The accompanying notes are an integral part
of these unaudited condensed consolidated financial statements.
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
Notes to Condensed Consolidated Financial Statements
March 31, 2017, and December 31, 2016
NOTE 1 – CONDENSED FINANCIAL STATEMENTS
The accompanying financial
statements of Dthera Sciences (the “Company”) have been prepared by the Company without audit. In the opinion of management,
all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of
operations, and cash flows at March 31, 2017, and for all periods presented herein, have been made.
Certain information
and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally
accepted in the United States of America (“U.S. GAAP”) have been condensed or omitted. It is suggested that these condensed
financial statements be read in conjunction with the financial statements and notes thereto included in the Company's December
31, 2016 audited financial statements. The results of operations for the periods ended March 31, 2017 and 2016 are not necessarily
indicative of the operating results for the full years.
NOTE 2 –
GOING CONCERN
The
Company's financial statements are prepared using U.S. GAAP applicable to a going concern which contemplates the realization of
assets and liquidation of liabilities in the normal course of business. As of the date of this Report, the Company had an accumulated
deficit of $2,465,477, working capital of $150,780, and no revenues to cover its operating costs, which raises substantial doubt
about its ability to continue as a going concern. As of the date of this Report, the Company had not yet established an ongoing
source of revenues sufficient to cover its operating costs and allow it to continue as a going concern.
The
future of the Company as an operating business will depend on its ability to (1) obtain sufficient capital contributions and/or
financing as may be required to sustain its operations and (2) to achieve adequate revenues from its operations. Management's plan
to address these issues includes, (a) continued exercise of tight cost controls to conserve cash, (b) obtaining additional financing,
(c) placing revenue producing services into place (d) identifying and executing on additional revenue generating opportunities.
The
ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described
in the preceding paragraph and eventually secure other sources of financing and attain profitable operations. The accompanying
financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.
If the Company is unable to obtain adequate capital, it could be forced to cease operations.
NOTE 3 – SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES
Nature of Business
Dthera Sciences (formerly Knowledge
Machine International, Inc.) is a Nevada corporation, and was incorporated on December 27, 2012.
The Company offers a subscription-based service
that captures, shares, and stores photos and audio in cloud. It offers a Platform, which enables users to preserve and share memories,
and will initially target a Quality of Life benefit in certain patient populations, principally patients suffering from Alzheimer’s
disease and dementia. On September 21, 2016, the Company acquired a new operating subsidiary, EveryStory, Inc., a Delaware corporation
(“EveryStory”). Following the acquisition (referred to herein as the “EveryStory Transaction”), the Company’s
business is to develop a Digital Therapeutic technology designed to deliver Reminiscence Therapy to certain patient populations,
principally patients suffering from Alzheimer’s disease and dementia with the goal of a Quality of Life benefit and reduction
in anxiety in those populations. As of the date of this Report, EveryStory was our only subsidiary. In connection with the EveryStory
transaction, the Company dissolved its other former subsidiary entity and terminated its prior business operations.
Acquisition
of EveryStory; EveryStory Transaction
.
On September 21, 2016, the Company entered
into an Amended and Restated Acquisition and Share Exchange Agreement (the “A&R Agreement”) with EveryStory, Inc.,
a Delaware corporation (“EveryStory”), and each of its shareholder (the “EveryStory Holders”), and closed
the acquisition (the “Acquisition”) of the ownership of EveryStory (the “Closing”). The agreement between
the Company and the EveryStory management was that following the Closing, the EveryStory Holders would own 55% of the outstanding
shares of the Company’s common stock on a fully converted basis, and the legacy shareholders of the Company would
own 45% of the shares, and that the Company would have between $500,000 and $1,000,000 in available cash and no debt.
The Company acquired all of the outstanding
shares of EveryStory, and agreed to issue an aggregate of 15,477,604 shares of the Company’s common stock to the EveryStory
holders, with the understanding that an additional 4,388,997 shares were issued to holders of EveryStory convertible debt instruments
which are convertible or exercisable into shares of EveryStory common stock (collectively, the “Exchange Shares”).
Additionally, prior to Closing, the parties agreed that certain shares of the Company’s common stock were to be returned
to the Company for cancellation, resulting in the current Company’s shareholders owning an aggregate of 8,000,000 shares
of the Company’s common stock immediately prior to the Closing.
Pursuant to the A&R Agreement, the 19,866,601
Exchange Shares issued or to be issued to the EveryStory Holders constituted 75% of the total issued and outstanding shares of
the Company’s common stock, and the legacy Company shareholders (who were the owners of the Company’s common stock
immediately prior to the Closing) owned an aggregate of 40,875,000 shares, which constituted 25% of the total outstanding Company
common stock.
The Company’s and EveryStory’s
management agreed, and the A&R Agreement provided, that following the Closing, the Company would conduct a reverse stock split
(discussed in more detail below), following which the outstanding shares of the Company’s Series A Preferred Stock would
convert into a total of 8,000,000 shares of common stock. Following such conversion, the EveryStory owners would own or have the
right to receive shares of the Company’s common stock equal to 55% of the then-outstanding Company common stock, and the
Company legacy shareholders would own shares of the Company’s common stock equal to 45% of the then-outstanding Company common
stock, consisting of 8,000,000 shares of Company common stock issued on conversion of the Company’s Series A Preferred Stock
(22.5%) and 8,000,000 shares of the Company’s common stock owned by the other legacy Company shareholders (22.5%).
As a result of the Closing of the A&R Agreement,
EveryStory became our wholly owned subsidiary. Additionally (as discussed more fully below), our directors and officers immediately
prior to the Closing appointed the EveryStory management to become our new officers and directors, and then resigned from their
positions with us. In addition, we terminated our pre-closing business operations and agreed to dissolve our other wholly owned
subsidiary, Knowledge Machine.
Immediately prior to the Closing, there were
40,875,000 shares of the Company’s common stock. In connection with the Closing, the Company issued an aggregate of 15,477,604
shares to the EveryStory shareholders, and 4,388,997 shares were issued to the holders of EveryStory convertible debt instruments,
and the parties to the A&R Agreement understand and anticipate that all such holders would exercise and convert their securities
into the reserved shares of the Company.
Accounting Basis
The Company’s
financial statements are prepared using the accrual basis of accounting in accordance with U.S. GAAP.
Use of Estimates
The preparation of
financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements
and the reported amounts of revenue and expenses during the reporting periods. Significant estimates are made in relation to the
allowance for doubtful accounts and the fair value of certain financial instruments.
Principles of Consolidation
The consolidated financial statements include
the accounts of Dthera Sciences and its subsidiaries. All significant inter-Company accounts and transactions have been eliminated.
Fair Value of Financial Instruments
The Company measures assets and liabilities
at fair value based on an expected exit price as defined by the authoritative guidance on fair value measurements, which represents
the amount that would be received on the sale of an asset or paid to transfer a liability, as the case may be, in an orderly transaction
between market participants. As such, fair value may be based on assumptions that market participants would use in pricing an asset
or liability. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value
on either a recurring or nonrecurring basis whereby inputs, used in valuation techniques, are assigned a hierarchical level.
The following are the hierarchical levels of
inputs to measure fair value:
|
Level 1 - Observable inputs that reflect quoted market prices in active markets for identical assets or liabilities.
|
|
|
|
Level 2 - Inputs reflect quoted prices for identical assets or liabilities in markets that are not active; quoted prices for similar assets or liabilities in active markets; inputs other than quoted prices that are observable for the assets or liabilities; or inputs that are derived principally from or corroborated by observable market data by correlation or other means.
|
|
|
|
Level 3 - Unobservable inputs reflecting the Company's assumptions incorporated in valuation techniques used to determine fair value. These assumptions are required to be consistent with market participant assumptions that are reasonably available.
|
The carrying amounts of the Company's financial
assets and liabilities, such as cash, prepaid expenses, other current assets, accounts payable & accrued expenses, certain
notes payable and notes payable - related party, approximate their fair values because of the short maturity of these instruments.
The Company accounts for its derivative liabilities,
at fair value, on a recurring basis under level 2.
Embedded Conversion Features
The Company evaluates embedded conversion features
within convertible debt under Accounting Standards Codification (“ASC”) 815, "Derivatives and Hedging" to
determine whether the embedded conversion feature(s) should be bifurcated from the host instrument and accounted for as a derivative
at fair value with changes in fair value recorded in earnings. If the conversion feature does not require derivative treatment
under ASC 815, the instrument is evaluated under ASC 470-20 "Debt with Conversion and Other Options" for consideration
of any beneficial conversion feature.
Derivative Financial Instruments
The Company does not use derivative instruments
to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of it financial instruments, including
stock purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives.
For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at
its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to income.
For option-based simple derivative financial
instruments, the Company uses the Black-Scholes option-pricing model to value the derivative instruments at inception and subsequent
valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities
or as equity, is re-assessed at the end of each reporting period.
Debt Issue Costs and Debt Discount
The Company may record debt issue costs and/or
debt discounts in connection with raising funds through the issuance of debt. These costs may be paid in the form of cash, or equity
(such as warrants). These costs are amortized to interest expense over the life of the debt. If a conversion of the underlying
debt occurs, a proportionate share of the unamortized amounts is immediately expensed.
Stock-Based Compensation
The Company accounts for share based payments
in accordance with ASC 718, Compensation - Stock Compensation, which requires all share-based payments to employees, including
grants of employee stock options, to be recognized in the financial statements based on the grant date fair value of the award.
In accordance with ASC 718-10-30-9, Measurement Objective – Fair Value at Grant Date, the Company estimates the fair value
of the award using a valuation technique. For this purpose, the Company uses the Black-Scholes option pricing model. The Company
believes this model provides the best estimate of fair value due to its ability to incorporate inputs that change over time, such
as volatility and interest rates, and to allow for actual exercise behavior of option holders.
Compensation cost is recognized over the requisite
service period which is generally equal to the vesting period. Upon exercise, shares issued will be newly issued shares from authorized
common stock.
ASC 505, "Compensation-Stock Compensation",
establishes standards for the accounting for transactions in which an entity exchanges its equity instruments to non-employees
for goods or services. Under this transition method, stock compensation expense includes compensation expense for all stock-based
compensation awards granted on or after January 1, 2006, based on the grant-date fair value estimated in accordance with the provisions
of ASC 505.
Loss Per Share
Basic loss per Common
Share is computed by dividing losses attributable to Common shareholders by the weighted-average number of shares of Common Stock
outstanding during the period.
Diluted loss per Common
Share is computed by dividing loss attributable to Common shareholders by the weighted-average number of Shares of Common Stock
outstanding during the period increased to include the number of additional Shares of Common Stock that would have been outstanding
if the potentially dilutive securities had been issued. Potentially dilutive securities include outstanding convertible Preferred
Stock, stock options, warrants, and convertible debt. The dilutive effect of potentially dilutive securities is reflected in diluted
earnings per share by application of the treasury stock method. Under the treasury stock method, an increase in the fair market
value of the Company’s Common Stock can result in a greater dilutive effect from potentially dilutive securities.
For
the three months ended March 31, 2017 and 2016, all of the Company’s potentially dilutive securities (warrants, options,
convertible preferred stock, and convertible debt) were excluded from the computation of diluted earnings per share as they were
anti-dilutive. The total number of potentially dilutive Common Shares that were excluded were 3,443,916 for the three months ended
March 31, 2017.
Reclassification
Certain balances in previously issued financial statements have
been reclassified to be consistent with the current period presentation.
Recent Accounting Pronouncements
In March 2016, the
Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-09
Compensation
– Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting
(“ASU 2016-09”).
ASU 2016-09 was issued as part of the FASB’s simplification initiative and intends to improve the accounting for share-based
payment transactions. The areas for simplification in this ASU involve several aspects of the accounting for share-based payment
transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification
on the statement of cash flows. Some of the areas for simplification apply only to nonpublic entities. The ASU is effective for
annual and interim periods in fiscal years beginning after December 15, 2016. Early adoption is permitted in any interim or annual
period provided that the entire ASU is adopted. If an entity early adopts the ASU in an interim period, any adjustments should
be reflected as of the beginning of the fiscal year that includes that interim period. The adoption of this standard did not have
a material impact on our consolidated financial statements.
Management has considered
all other recent accounting pronouncements issued since the last audit of our consolidated financial statements. The Company’s
management believes that these recent pronouncements will not have a material effect on the Company’s consolidated financial
statements.
NOTE 4 – PROPERTY AND EQUIPMENT
The Company’s
property and equipment were comprised of the following as of March 31, 2017, and December 31, 2016:
|
|
March 31,
2017
|
|
|
December 31,
2016
|
|
Computer & Equipment
|
|
$
|
2,816
|
|
|
$
|
2,816
|
|
Less: Accumulated Depreciation
|
|
|
(2,080
|
)
|
|
|
(1,902
|
)
|
Net Property and Equipment
|
|
$
|
736
|
|
|
$
|
914
|
|
Depreciation expense for the three months
ended March 31, 2017 and 2016, was $176 and $237, respectively.
NOTE 5 – INTANGIBLE ASSETS
The Company’s
intangible assets were comprised of the following of March 31, 2017, and December 31, 2016:
|
|
March 31,
2017
|
|
|
December 31,
2016
|
|
Technology asset purchase
|
|
$
|
–
|
|
|
$
|
58,960
|
|
Less: Accumulated Amortization
|
|
|
–
|
|
|
|
–
|
|
Less: Impairment
|
|
|
–
|
|
|
|
(58,960
|
)
|
Net Intangible Assets
|
|
$
|
–
|
|
|
$
|
–
|
|
The Company impaired
intangible assets related to the technology asset purchase and patent purchase due to no revenue production, totaling $0 and $58,960,
for the three months ended March 31, 2017 and 2016, respectively.
NOTE 6 – LOANS PAYABLE
Notes Payable
Notes payable consisted of the following
as of March 31, 2017, and December 31, 2016:
Balance December 31, 2016
|
|
$
|
20,000
|
|
Cash additions
|
|
|
50,000
|
|
Expense additions
|
|
|
–
|
|
Cash payments
|
|
|
–
|
|
Conversions
|
|
|
–
|
|
Balance March 31, 2017
|
|
$
|
70,000
|
|
On
August 3, 2016, the Company entered into a promissory note purchase agreement with an unrelated individual for $20,000. This note
was due on demand. As disclosed in Note 12, the Company repaid this promissory note on April 13, 2017.
On
February 3, 2017, the Company issued a short-term note to an unrelated party individual for $50,000 due on demand. The note bore an
interest rate of 10% per annum interest within the 90 day period and will increase to 20% interest if not fully paid back within
90 days. As disclosed in Note 12, on April 9, 2017, the Company repaid the full balance of $50,000.
Convertible Notes Payable
Notes payable due to non-related parties
consisted of the following as of March 31, 2017, and December 31, 2016:
Balance December 31, 2016
|
|
$
|
67,345
|
|
Cash Payments
|
|
|
(240,000
|
)
|
Conversions
|
|
|
–
|
|
Debt discount
|
|
|
172,655
|
|
Balance March 31, 2017
|
|
$
|
–
|
|
Effective September 22, 2016, the Company conducted
a private offering of convertible notes (the “Note Offering”) to raise additional capital that would remain in the
Company following the Closing of the EveryStory Transaction. In the convertible note offering, the Company raised an aggregate
of $240,000, which was to be a component of the post-Closing capitalization of the Company. In the Note Offering, investors entered
into a securities purchase agreement (the “Note SPA”) and were issued a convertible redeemable promissory note (collectively,
the “Convertible Notes”). Pursuant to the terms of the Note SPA, each investor represented and warranted that it was
an accredited investor and that he or she was purchasing the Convertible Notes for his or her own account, and not with a view
to distribution, as well as other standard representations made in private transactions. Also pursuant to the Note SPA, the Company
has the right to put an additional Convertible Note (in the same principal amount as purchased by the applicable investor) beginning
on January 3, 2017, subject to certain conditions. The Convertible Notes bore interest at a rate of 10%, and were to mature on
September 13, 2017, if not converted or prepaid prior to that. The Convertible Notes could convert into shares of the Company's
common stock at a price for each share of Common Stock equal to 65% of the lowest closing bid price of the Common Stock as reported
on the OTC Market platform on which the Company’s shares are quoted or any exchange upon which the Common Stock may be traded
in the future ("Exchange"), on the date of the closing of the EveryStory Transaction. Up to 50% of the Convertible Notes
could be repaid by the Company any time prior to 180 days after the issuance of the Convertible Notes, with a 30% premium to be
paid in connection with the prepayment. As a result of this transaction a debt discount of $240,000 was recorded against the note.
As of March 31, 2017, interest expense of $172,655 was recorded as part of the amortization of the debt discount, leaving a debt
discount balance of $0.
In March 2017, the Company modified the interest
rate on the Convertible Notes to 15% per annum and repaid the Convertible Notes in the original principal amount of $240,000. In
connection with the repayment of the Convertible Notes, the Company repaid a total of $240,000 in principal and $18,000 in interest,
and agreed to issue 83,300 shares of the Company’s common stock to the holders of the Convertible Notes. The shares of stock
were issued pursuant to Section 4(a)(2) of the Securities Act of 1933 and regulations promulgated thereunder. Each of the holders
of the Convertible Notes represented to the Company that it was an accredited investor, that it was acquiring the shares for its
own account and for investment purposes, and not with an intent to distribute.
The Company
evaluated amendment under ASC 470-50, “
Debt - Modification and Extinguishment”
, and concluded that the additional
shares issued and increase in annual interest rate did result in significant and consequential changes to the economic substance
of the debt and thus resulted in loss on extinguishment of the debt of $91,593.
NOTE 7 –DERIVATIVE LIABILITIES
The Company evaluates
its fair value hierarchy disclosures each quarter. The Company has convertible notes with embedded conversion features, which is
accounted for as a derivative liability and measured at fair value on a recurring basis. As of March 31, 2017 this derivative liability
had an estimated fair value of $0.
The following table
presents information about our derivative liability, which was our only financial instrument measured at fair value on a recurring
basis using significant inputs other than level one inputs that are either directly or indirectly observable (Level 2) as of
March 31, 2017:
Balance at December 31, 2016
|
|
$
|
234,502
|
|
Conversion
|
|
|
(91,667
|
)
|
Change in Fair Value of Derivative
|
|
|
(142,835
|
)
|
Balance at March 31, 2017
|
|
$
|
–
|
|
The fair value of
this derivative liability was calculated using the multinomial lattice models that value the derivative liability within the notes
based on a probability weighted discounted cash flow model. These models are based on future projections of the various potential
outcomes. The features in the notes that were analyzed and incorporated into the model included the conversion feature with the
reset provisions; redemption provisions; and the default provisions. Assumptions used to calculate the fair value of the derivative
liability were as follows:
|
|
March 31,
|
|
|
2017
|
Expected term in years
|
|
0.51 years
|
Risk-free interest rates
|
|
0.89%
|
Volatility
|
|
48.05%
|
Dividend yield
|
|
0%
|
In addition to the assumptions above, the
Company also takes into consideration whether or not the Company would participate in another round of financing and if that financing
is registered or not and what that stock price would be for the financing at that time. The Company notes that the notes have matured
and is no longer calculating a derivative value for these notes.
NOTE 8 –PREFERRED STOCK
The Company has authorized 1,000,000 shares
of Preferred Stock, of which it has designated 150,000 shares of $0.0001 par value per share Series A Redeemable Preferred Stock.
The Series A Preferred Stock has a stated value of $1.00 per share, of which 112,690 and 112,690 shares were issued and outstanding
as of March 31, 2017, and December 31, 2016, respectively.
On September 13, 2016,
the Company issued the 112,690 shares of A Preferred Stock to the CEO and CTO in exchange for amounts owed to them which included
$6,096 of accrued expenses, $95,591 of related party loans, $10,000 of convertible notes payable and $1,003 of accrued interest
on the convertible notes payable. The shares of Series A Preferred stock are redeemable at any time for cash on a dollar-per-dollar
basis at a redemption price of $1.00 per share. If not redeemed for cash, according to the A&R Agreement the shares of Series
A Preferred Stock can be converted into shares of Common Stock using a post-split conversion price of $0.10 per share pursuant
to the A&R Agreement.
Series A Redeemable
Preferred Stock
The Series A Preferred Stock have the following
rights and preferences:
|
·
|
Redeemable at any time at the option of the holder for cash on a dollar-per-dollar basis at a redemption of $1.00 per share.
|
|
·
|
Convertible into shares of Common Stock using a conversion price of $0.10 per share.
|
|
·
|
No general voting rights until converted into Common Stock.
|
|
·
|
Entitled to receive dividends at a rate per annum of 8%
|
|
·
|
Liquidation preference upon a liquidation event.
|
NOTE 9
– COMMON STOCK
The Company has authorized 200,000,000 shares
of $0.001 par value per share Common Stock, of which 41,494,401 and 36,181,101 shares were issued outstanding as of March 31, 2017,
and December 31, 2016, respectively.
Three Months Ended March 31, 2017
During
three months ended March 31, 2017, pursuant to a private placement offering (the “Private Offering”) the Company issued
5,230,000 shares of common stock for gross proceeds of approximately $846,000, with $10,000 in stock subscriptions receivable.
On March 10, 2017,
the Company issued 83,300 shares of the Company’s common stock to the holders of the Convertible Notes as part of the
modification and settlement of the notes, fair-valued at $183,260.
Year Ended December 31, 2016
On June 5, 2016,
EveryStory
issued 88,000 shares of its common stock, which were exchanged for 616,133 shares of Dthera common stock for the purchase agreement
for an SIT Patent for a value of $58,960.
On August 3, 2016,
EveryStory
issued
10,000 shares of its common stock, which exchanged for
70,015 shares of Dthera common stock, for a value of $6,700 of accrued interest.
On September 15, 2016, EveryStory issued 25,000
shares of its common stock, which were exchanged for 175,038 shares of Dthera common stock valued at $16,750 for services
.
On September 16, 2016, EveryStory issued 37,500
shares of its common stock, which were exchanged for 263,325 shares of Dthera common stock valued at $25,125 in settlement of $60,000
of accrued consulting fees
. This resulted in a gain on settlement of $34,875.
On September
21, 2016, as part of the A&R Agreement, EveryStory issued 625,033 shares of its common stock, which were exchanged for 4,388,997
shares of Dthera common stock, for the conversion of debt for a value of $730,174.
In connection with the A&R Agreement,
the parties agreed that the prior shareholders of the Company would own an aggregate of 16,000,000 post-split shares of the Company’s
common stock as part of the agreement totaling $56,354. The reverse stock split is discussed in more detail in Note 1 above.
From November to December 2016, the Company
issued 314,500 shares of common stock at $0.20 per share for cash proceeds of $62,900, pursuant to the Private Offering.
NOTE
10 – STOCK PURCHASE OPTIONS
Stock Purchase
Options
During the three months
ended March 31, 2017, the Company did not issue any stock purchase options. As the options holders are non-employees, the values
attributable to these options are remeasured on a quarterly basis and amortized over the service period and until they have fully
vested over a 3 year vesting period. The Company believes that the fair value of the stock options is more reliably measurable
than the fair value of the services received. The fair value of the stock options granted was revalued at each reporting date using
the Black-Scholes valuation model. As of March 31, 2017, the Company remeasured the options at a value of $1,904,715 to be recognized
over the vesting period, of which $189,154 has been recognized.
During the year ended
December 31, 2016, EveryStory issued non-employee options to purchase a total of 106,100 shares of EveryStory common stock, which
would exchange for 742,860 shares of Dthera common stock, which were originally valued at $63,678. EveryStory issued the options
in conjunction with services. The EveryStory options were converted into Dthera options on September 21, 2016, pursuant to the
A&R Agreement. As the options holders are non-employees, the values attributable to these options are remeasured on a quarterly
basis and amortized over the service period and until they have fully vested over a 3 year vesting period. The Company believes
that the fair value of the stock options is more reliably measurable than the fair value of the services received. The fair value
of the stock options granted was revalued at each reporting date using the Black-Scholes valuation model. As of December 31, 2016,
the Company remeasured the options at a value of $1,609,669 to be recognized over the vesting period, of which $199,969 has been
recognized.
The following table
summarizes the changes in options outstanding of the Company during the three months ending March 31, 2017:
|
|
Number of
Options
|
|
|
Weighted
Average
Exercise
Price $
|
|
Outstanding, December 31, 2016
|
|
|
4,146,994
|
|
|
|
0.10
|
|
|
|
|
|
|
|
|
|
|
Outstanding, March 31, 2017
|
|
|
4,146,994
|
|
|
|
0.10
|
|
|
|
|
|
|
|
|
|
|
Exercisable, March 31, 2017
|
|
|
3,404,134
|
|
|
|
0.10
|
|
As of March 31, 2017, the Company had $1,515,591 in unrecognized
expense related to future vesting of stock options.
NOTE
11 – FAIR VALUE MEASUREMENTS
Liabilities
measured at fair value on a recurring basis at March 31, 2017, are summarized as follows:
|
|
Level 1
|
|
|
Level 2
|
|
|
Level 3
|
|
|
Total
|
|
Fair value of options
|
|
$
|
–
|
|
|
$
|
1,904,715
|
|
|
$
|
–
|
|
|
$
|
1,904,715
|
|
Fair value of derivatives
|
|
$
|
–
|
|
|
$
|
–
|
|
|
$
|
–
|
|
|
$
|
–
|
|
Liabilities
measured at fair value on a recurring basis at December 31, 2016, are summarized as follows:
|
|
Level 1
|
|
|
Level 2
|
|
|
Level 3
|
|
|
Total
|
|
Fair value of options
|
|
$
|
–
|
|
|
$
|
1,609,699
|
|
|
$
|
–
|
|
|
$
|
1,609,699
|
|
Fair value of derivatives
|
|
$
|
–
|
|
|
$
|
234,502
|
|
|
$
|
–
|
|
|
$
|
234,502
|
|
Fair value is calculated using the Black-Scholes options pricing
model.
NOTE 12- SUBSEQUENT EVENTS
In accordance with ASC 855, Company’s
management reviewed all material events through the date of this filing and determined that there were the following material subsequent
events to report:
During
April 2017, pursuant to the Private Offering, the Company issued 1,575,000 shares of common stock for gross proceeds of approximately
$315,000.
On
April 9, 2017, the Company paid in full the promissory note dated February 3, 2017, in the amount of $50,000.
On April 13, 2017
the Company paid
in full the promissory note purchase agreement entered into on August 3,
2016, with an unrelated individual for $20,000.